Allopurinol and Endothelial Function in Diabetic CAD Patients
NCT ID: NCT03385135
Last Updated: 2017-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
58 participants
INTERVENTIONAL
2017-12-31
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Allopurinol in Acute Coronary Syndrome
NCT03745729
Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
NCT04368819
Evaluation of PK and Safety of D-0120 and Allopurinol
NCT05360628
Effect of Allopurinol Treatment on Insulin Resistance
NCT02008968
Microalbuminuria and Allopurinol in Type 1 Diabetes
NCT02829177
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allopurinol group
Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
Allopurinol
300 mg for 4 weeks then 600 mg for 4 weeks in the active group
No Allopurinol group
Optimal medical therapy alone
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allopurinol
300 mg for 4 weeks then 600 mg for 4 weeks in the active group
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Known coronary artery disease with previous percutaneous coronary intervention and optimal medical therapy for at least one month
Exclusion Criteria
* creatinine clearance \<60ml/min
* Known history of gout disease or ongoing treatment with allopurinol
* Allergy to allopurinol
* Inability to provide informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Tunis El Manar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kasbaoui sami
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salem Kachboura, MD
Role: STUDY_CHAIR
Cardiology Department, Abderrahmen Mami Hospital, 2008, Ariana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Department, Abderrahmen Mami Hospital
Aryanah, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALLIENCE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.